Industries

• Medical
• Health Medical
• Health Technology
• Manufacturing

Idea

The biopharmaceuticals project aims to establish a specialized facility for pharmaceutical manufacturing and medical laboratories, in partnership with international pharmaceutical companies. This facility will focus on utilizing genetic engineering techniques within living cells derived from various biological sources to treat complex diseases. These advanced techniques are particularly effective in managing chronic conditions such as cancer, arthritis, multiple sclerosis, and autoimmune diseases. Biological medications, developed through this process, offer significant advantages over conventional drugs. They target diseased cells with greater precision, enhance recovery rates, and reduce the incidence of treatment-related side effects.

---

Challenge

There is a global increase in the prevalence of chronic diseases, cancer, and infectious diseases, particularly in Saudi Arabia and the Middle East. Despite an abundance of scientific research and experiments, many of these advancements do not reach practical application.
Recent statistics from the Cancer Control Program at the Saudi Ministry of Health reveal that leukemia is the most common childhood cancer among Saudis, accounting for 38.8% of cases. The overall cancer rate is 52.6 cases per 100,000 citizens, placing Saudi Arabia among the countries with the highest cancer rates globally.
Obesity is also a significant health concern in Saudi Arabia, ranking 15th among the world's fattest countries. This is followed by diabetes, with complications leading to approximately 5,000 amputations annually. Type 2 diabetes has a high prevalence rate of 32.8%, which is projected to rise to 45.36% by 2030.
Hypertension is another major issue, with blood pressure levels increasing with age. Among those aged 15-24, the prevalence is 3.2%, rising to 51.2% for individuals aged 55-64, and reaching 70% for those aged 65 and above. Additionally, hereditary diseases are prevalent in Saudi Arabia and the Gulf countries, often due to consanguineous marriages.
Despite the wealth of valuable research and scientific experiments, many of these innovations fail to be fully utilized and eventually fade away.

---

Solution

By bringing together talented and innovative scientists in molecular biology and genomics, we aim to foster a cutting-edge pharmaceutical industry tailored to the needs of the Saudi and Gulf markets, significantly boosting the Kingdom's economy. Aligned with Vision 2030, our partnership in research, development, and manufacturing will form a robust first line of defense against epidemiological risks in the Kingdom.
This initiative will integrate the biopharmaceutical industry sector by consolidating laboratories, researchers, manufacturers, and marketers in one location. For instance, our scientific research laboratories will provide advanced technologies that collaborate with global pharmaceutical companies to develop new drugs, effectively marketing innovative solutions.
We will establish partnerships and collaborate with universities and medical laboratories to spotlight verified research and development products. Our approach will encompass both Business-to-Business (B2B) and Business-to-Consumer (B2C) systems, leveraging investment opportunities in these sectors.